IDH2 and glioblastoma: Several emerging research areas hold particular promise, such as tailored therapies based on molecularly defined subtypes of GBM (e.g., IDH-mutant vs. wild-type, EGFR-amplified vs. mesenchymal phenotypes) and using metabolic profiling for personalized treatment selection.